FIG. 2.

CD11d monoclonal antibody (mAb) treatment reduces neutrophil and macrophage/microglia numbers in the injured mouse spinal cord 14 days post-injury. (A and C) Shown are representative photomicrographs of sections from the lesion epicenters of 1B7 and CD11d mAb-treated mice 14 days after spinal cord injury (SCI), immunostained with a Ly-6G antibody. (B) CD11d mAb treatment (gray bar) significantly reduced the number of neutrophils (Ly-6G⁺ cells) compared to controls (1B7, open bar). (C) Representative photomicrographs of sections at the epicenter or 960 μm caudal or rostral to the epicenter from anti-CD11d or control 1B7 mAb-treated mice stained with a Mac-1 antibody. Mac-1-expressing cells were large, foamy, and round at the lesion epicenters in both CD11d and 1B7 mAb-treated mice, and caudal to the epicenter in 1B7 mAb-treated mice. Rostral to the lesions in both CD11d and 1B7 mAb-treated mice, and caudal to the lesion epicenter in CD11d mAb-treated mice, the majority of Mac-1⁺ cells were stratified, with small cell bodies bearing multiple processes. (D) CD11d mAb (gray bars) treatment significantly reduced the percent area of Mac-1-immunoreactivity caudal to the lesion compared to controls (1B7, open bars; scale bars in A and C = 100 μm, 50 μm in high-power insets). In B and D values are means ± standard error (in B *p<0.05 significantly different from controls by two-tailed Student’s t-test, 6 mice/group; in D *p=0.025 by two-way analysis of variance and p<0.05 by Fisher protected t-test, 6 mice/group).